The Kenema lab and patient ward have become the epicenter of the current Ebola outbreak in Eastern Sierra Leone. Our facility processed 94% of the patients and samples in the first 24 days of the outbreak. However, during this outbreak, the funding that supports staff salaries was not renewed.
It is with great sadness that the VHFC mourns the loss of our colleague and friend Dr. Sheik Humarr Khan, Physician In-Charge of the Lassa Fever Program at Kenema Government Hospital in Sierra Leone. Dr. Khan was a leading expert in the clinical care of viral hemorrhagic fevers, devoted to the care of his fellow nationals. Dr.
KENEMA, Sierra Leone - The Viral Hemorrhagic Fever Consortium (VHFC) remains deeply concerned about the ongoing outbreak of Ebola Virus Disease (EVD) in West Africa. As of 27 June 2014, the WHO reports 176 cases and 46 deaths from confirmed cases in Sierra Leone.
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and VHFC partner, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit.
In an interview on National Public Radio, Drs. Robert Garry (Tulane University) and Thomas Geisbert (University of Texas Medical Branch) discuss the devastation caused by the raging Ebola outbreak in West Africa, and the challenges health workers are facing.
In a recent article by Today.com, Dr. Robert Garry discusses the growing threat of Ebola in Sierra Leone. Dr. Garry, a researcher from Tulane University, has worked on building research capacity on viral hemorrhagic fevers in Sierra Leone for a decade.
May 27, 2014 - The Viral Hemorrhagic Fever Consortium (VHFC) is very concerned about the recent deaths from Ebola Virus Disease in Koindu, Kailahun District bordering the current Ebola epicenter of Gueckedou, Guinea. Seven samples from that area have since been confirmed to be positive for Zaire ebolavirus at the Lassa Laboratory at Kenema Government Hospital (KGH).
VHFC researchers at Tulane University have published findings in the Journal of Virology on an antiviral peptide with potential implications for Lassa fever (LF) treatment. Unlike ribavirin, the only drug currently used to treat LF, the peptide is not acutely toxic, and its activity is highly specific against arenaviruses.
VHFC researchers publish promising results from a five-year Lassa Fever trial conducted in post-conflict Sierra Leone. The trial demonstrated the ability of a rapid diagnostic test, developed by Corgenix Medical and other members of the Consortium, to quickly detect Lassa virus.